Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02655549
Other study ID # PF563-101
Secondary ID
Status Completed
Phase Phase 1
First received January 12, 2016
Last updated July 7, 2017
Start date December 2015
Est. completion date June 2017

Study information

Verified date July 2017
Source Pfenex, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.


Description:

This is a Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of Px563L or RPA563 administered intramuscularly. All subjects will be followed for safety and tolerability for 393 days after the initial vaccination. Immunogenicity analyses will be performed for up to 182 days, including an interim analysis based on Day 70 results, after the initial vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Willing and able to read and understand the consent process and sign an informed consent form (ICF).

- Females or males between the ages of 18 and 55, inclusive, at the time of informed consent.

- Healthy or with stable medical conditions not requiring continuous medication.

Exclusion Criteria:

- Female subjects who are pregnant or breastfeeding.

- A history of anthrax disease or receipt of an anthrax vaccine at any time in the past, exposure to or infection with B. anthracis, or has received any investigational anthrax vaccine or treatment (e.g., monoclonal antibodies, anthrax immune globulin).

- Positive test for human immunodeficiency virus (HIV), hepatitis C or hepatitis B (surface antigen).

- History of any malignant neoplasm or receipt of anti-neoplastic agents within the last 5 years, with the exception of adequately treated, localized or in situ non-melanoma of the skin (e.g., basal cell carcinoma) or of the cervix.

- History of immunodeficiency, chronic illness requiring continuous or frequent medical intervention, autoimmune disease, bleeding disorder, hemoglobinopathy, prior solid organ or bone marrow transplant, or any known history in the past 5 years of cardiac disease.

- Evidence of alcohol abuse (i.e., requiring treatment) or substance abuse (i.e., any use of illicit drugs) within 6 months prior to screening.

- History of severe allergy (e.g., anaphylaxis) to latex or rubber.

- Subjects who have significant scarring, tattoos, abrasions, rash, or other skin abnormality at the planned vaccination site that could interfere with evaluation of injection site..

- Use of any systemic steroids or other immunosuppressive agents within 2 years prior to screening; or use of topical, intranasal, or inhaled corticosteroids for =10 consecutive days within 1 year prior to screening.

- Administration of any licensed vaccines within 30 days prior to screening.

- History of anaphylaxis or other serious adverse reaction to vaccines.

- Donation or loss of >500 mL of blood or donation of plasma within 2 months of screening, or recipient of blood or blood products within 2 months of screening.

- Present or former member of US military or reservist who may have or will receive the licensed anthrax vaccine, or who has served in any military arena from January 1990 through present time.

- May be at risk for exposure to anthrax or may be required to receive the licensed anthrax vaccine (e.g., postal workers).

- Has previously participated in any anthrax vaccine or anti-protective antigen (PA) monoclonal antibody clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Px563L, RPA563, or placebo
Two intramuscular injections

Locations

Country Name City State
United States Quintiles Phase One Services Overland Park Kansas

Sponsors (2)

Lead Sponsor Collaborator
Pfenex, Inc Department of Health and Human Services

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events (AE) and adverse events of special interest (AESI) for vaccines 393 days
Secondary Anthrax toxin neutralizing antibody (TNA) 50% neutralization factor (NF50) value 182 days
See also
  Status Clinical Trial Phase
Completed NCT00114621 - Anthrax Vaccine Clinical Trials Phase 1
Recruiting NCT00050310 - Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Completed NCT01453907 - Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers Phase 1
Completed NCT01491607 - Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Phase 3
Completed NCT03518125 - BARDA Securing Anthrax Immunity For the Elderly Phase 2
Completed NCT04660201 - Anthrax AV7909 Liquid vs Lyophilized Phase 1
Completed NCT04320485 - Evaluation of the Clinical Specificity of the Active Anthrax Detectâ„¢ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
Recruiting NCT06365073 - A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
Completed NCT03877926 - VELOCITY: An Anthrax Vaccine Clinical Study Phase 3
Completed NCT03498027 - Febrile Whole Blood Specimen Collection and Testing
Terminated NCT00964834 - Ph1 Study of Valortim and Doxycycline in Humans Phase 1
Completed NCT00063843 - Anthrax-rPA: Safety, Tolerability, Immunogenicity Phase 1
Completed NCT01624532 - A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Phase 2
Completed NCT04148118 - A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults Phase 1
Terminated NCT05672875 - Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
Completed NCT01770743 - A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Phase 2
Completed NCT01867957 - Efficacy and Safety of Anthrax Vaccine, GC1109 Phase 1
Completed NCT00845650 - Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) Phase 1/Phase 2
Completed NCT00031291 - Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin N/A
Not yet recruiting NCT03569514 - Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax